close read more

A differentiated geographical footprint

FRÉDÉRIC SESINI

Executive Vice President World Operations


HOW IS SERVIER MEETING THE SPECIFIC NEEDS OF PATIENTS?

Thanks to our differentiated geographical footprint, we are able to adapt to the specificities of each country. This close proximity to patients and health care professionals is essential to gaining a better understanding of the diversity of health care needs and responding to them through specific adaptations. We also rely on a global therapeutic range: our portfolio of brand-name and generic medicines is tailored to each market. In addition, with the new organization that we’ve implemented, based on market typology, we are able to address each country’s specificities more efficiently.

 

HOW STRONG IS SERVIER AS A GLOBAL PLAYER?

Our very strong global presence provides us with a level of geographic coverage that’s unique for a group of our size. In the countries where we operate, our presence is ensured by teams covering multiple activities (market access, advertising, medical affairs, etc.) and who collaborate very well with each other. Their high level of qualification and universally recognized medical expertise guarantee us a solid partnership with local health care actors. The strength of our team and the diversity of our portfolio enable us to position ourselves as a key player in emerging markets with high therapeutic needs. At the same time, we are active in “mature” countries, where our innovative solutions include oncology for colorectal cancer and the treatment of certain leukemias.

 

WHAT ARE YOUR PRIORITIES IN TERMS OF GEOGRAPHIC EXPANSION?

We wish to pursue our international development with the aim of maintaining a differentiated geographical footprint. Our ambition is to maintain strong growth in BRC (Brazil, China, Russia), develop our presence in the United States and Japan through our oncology portfolio, and also support the development of emerging countries, particularly in Africa and Asia, in order to provide access to our medicines to the largest possible population. In countries where Servier is already well established, we wish to consolidate our positions, particularly in Europe.